LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free earnings report on Neogen Corp. (NASDAQ: NEOG), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NEOG. Neogen reported its fourth quarter and fiscal 2018 operating and financial results on July 17, 2018. The maker of medical testing kits outperformed top- and bottom-line expectations. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Neogen most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=NEOG

Earnings Highlights and Summary

For the fourth quarter of its fiscal year 2018, Neogen announced revenues of $109.29 million, reflecting an increase of 11% compared to revenue of $98.85 million in Q4 FY17. The Company?s reported numbers beat analysts? estimates of $107.8 million.

Neogen?s revenues for the entire fiscal 2018 increased 11% to $402.25 million compared to $361.59 million in FY18.

Neogen?s gross margins were 45.4% for Q4 FY18 compared to 47.6% in Q4 FY17. The Company?s operating income was $19.9 million, or 18.2% of sales, in the for the reported quarter compared to $19 million, or 19.2% of sales, recorded in the prior year?s same quarter.

For Q4 FY18, Neogen?s net income was $17.55 million, reflecting an increase of 41% compared to Q4 FY17 earnings of $12.47 million. Adjusted for a 4-for-3 stock split effective December 29, 2017, the Company?s earnings were $0.33 per share in the reported quarter compared to $0.24 per share in the year ago corresponding period. Neogen?s earnings surpassed Wall Street?s estimates of

Neogen?s net income for the full 2018 fiscal year surged 44% to $63. 15 million, or $1.21 per share, compared to the prior year's $43.79 million, or $0.86 per share. In both Q4 FY18 and FY17, the Company benefitted from US corporate tax reform enacted in December 2017 and changes in the recognition of excess tax benefits from employee stock option exercises, which contributed to an effective tax rate of 12% for the reported quarter and 14% for the reported period.

Neogen?s Segment Results

During FY18, revenues for the Food Safety segment increased 14% to $196.0 million on a y-o-y basis compared to $171.3 million in FY17, aided in part by the acquisitions of Quat-Chem and Rogama. The segment's FY18 results included a 13% increase in sales of test kits to detect drug residues in milk, in part driven by new test kits to detect drug residues of special concern in Eastern Europe.

For FY18, Neogen's revenues from international sources increased to 37.6% of total revenues compared to 35.8% in the prior year, aided in part by acquisitions. For FY18, the Animal Safety segment reported a revenue increase of 8% to $206.2 million, led by strong growth in the genomics business; a 15% increase in sales of its animal care line of products, an 11% increase in its rodent control product lines; a 13% increase in sales of drug detection products; and a 23% increase in sales of detectable needles.

Cash Matters

Neogen continue to produce strong cash flow, generating $22.5 million in cash from operations during the reported quarter and $69 million for the full year, while investing $21 million in property and equipment and other noncurrent assets for the year.

Neogen?s accounts receivable balances rose by 15% over levels at last year-end, with the increase attributable to the higher level of sales in the last 2 months of FY18 compared to FY17. The Company?s DSO remained constant at 60 days at each period-end.

Stock Performance Snapshot

July 19, 2018 - At Thursday?s closing bell, Neogen?s stock slightly dropped 0.12%, ending the trading session at $81.79.

Volume traded for the day: 229.31 thousand shares, which was above the 3-month average volume of 199.17 thousand shares.

Stock performance in the last month ? up 0.20%; previous three-month period ? up 17.03%; past twelve-month period ? up 63.03%; and year-to-date ? up 32.65%

After yesterday?s close, Neogen?s market cap was at $4.25 billion.

Price to Earnings (P/E) ratio was at 72.51.

The stock is part of the Healthcare sector, categorized under the Diagnostic Substances industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors